Nubeqa is a drug owned by Bayer Healthcare Pharmaceuticals Inc. It is protected by 8 US drug patents filed from 2019 to 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 27, 2038. Details of Nubeqa's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US10711013 | Androgen receptor modulating compounds |
Oct, 2030
(6 years from now) | Active |
| US9657003 | Androgen receptor modulating compounds |
Oct, 2030
(6 years from now) | Active |
| US11046713 | Androgen receptor modulating compounds |
Oct, 2030
(6 years from now) | Active |
| US8975254 | Androgen receptor modulating compounds |
Mar, 2033
(8 years from now) | Active |
| US10010530 | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(11 years from now) | Active |
| US10383853 | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(11 years from now) | Active |
| US11168058 | Manufacture of a crystalline pharmaceutical product |
Feb, 2038
(13 years from now) | Active |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10835515 | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nubeqa's patents.
Latest Legal Activities on Nubeqa's Patents
Given below is the list of recent legal activities going on the following patents of Nubeqa.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 Jan, 2024 | US10711013 |
| Patent Term Extension Certificate | 15 Feb, 2023 | US8975254 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Feb, 2023 | US10383853 |
| Notice of Final Determination -Eligible | 23 Nov, 2022 | US8975254 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Aug, 2022 | US8975254 |
| FDA Final Eligibility Letter | 29 Jul, 2022 | US8975254 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Dec, 2021 | US10010530 |
| Recordation of Patent Grant Mailed | 09 Nov, 2021 | US11168058 |
| Patent Issue Date Used in PTA Calculation | 09 Nov, 2021 | US11168058 |
| transaction for FDA Determination of Regulatory Review Period | 22 Oct, 2021 | US8975254 |
FDA has granted several exclusivities to Nubeqa. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Nubeqa, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Nubeqa.
Exclusivity Information
Nubeqa holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Nubeqa's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 30, 2024 |
| New Indication(I-900) | Aug 05, 2025 |
Several oppositions have been filed on Nubeqa's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Nubeqa's generic, the next section provides detailed information on ongoing and past EP oppositions related to Nubeqa patents.
Nubeqa's oppositions filed in EPO
Nubeqa has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 17, 2023, by Hamm&Wittkopp Patentanwälte Partmbb. This opposition was filed on patent number EP16704029A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP16704029A | Feb, 2023 | Hamm&Wittkopp Patentanwälte PartmbB | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Nubeqa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nubeqa's family patents as well as insights into ongoing legal events on those patents.
Nubeqa's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Nubeqa's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 27, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Nubeqa Generics:
There are no approved generic versions for Nubeqa as of now.
About Nubeqa
Nubeqa is a drug owned by Bayer Healthcare Pharmaceuticals Inc. It is used for treating non-metastatic castration-resistant prostate cancer. Nubeqa uses Darolutamide as an active ingredient. Nubeqa was launched by Bayer Healthcare in 2019.
Market Authorisation Date:
Nubeqa was approved by FDA for market use on 30 July, 2019.
NCE-1 date:
NCE-1 date is also known as the four year date as it is four years after the original drug approval. Since the approval date for Nubeqa is 30 July, 2019, its NCE-1 date is estimated to be 31 July, 2023
Active Ingredient:
Nubeqa uses Darolutamide as the active ingredient. Check out other Drugs and Companies using Darolutamide ingredient
Treatment:
Nubeqa is used for treating non-metastatic castration-resistant prostate cancer.
Dosage:
Nubeqa is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 300MG | TABLET | Prescription | ORAL |